Additional Relevant Details Synergy Pharmaceuticals presented new in vitro data at Digestive Disease Week (DDW) showing plecanatide, an investigational compound being evaluated for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), replicated the pH-dependent activity of the body’s naturally occurring gastrointestinal (GI) peptide – uroguanylin. Uroguanylin plays an important role in supporting regular bowel function through its activation of the intestinal guanylate cyclase C (GC-C) receptor.In vitro data presented today at DDW show that plecanatide, like uroguanylin, activates the GC-C receptor in a pH-dependent manner, and this may contribute to more frequent, well-formed bowel movements. While the under-secretion of fluid can cause constipation, the over-secretion of fluid can result in diarrhea. The balance of fluid secretion in the gut is normally achieved by a controlled – and pH-dependent – activation of the GC-C receptor by uroguanylin.